BACE1 and Alzheimer disease: Therefore, strategies combining partial BACE1 suppression with inhibition of the BACE1-elevating pathway (e.g., eIF2α phosphorylation) may be useful for increasing the therapeutic benefits while obviating the potential adverse effects in treating AD and related memory deficits.